Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement

Yiru Yan; Shiqiang Qu; Jinqin Liu; Chengwen Li; Xiao Yan; Zefeng Xu; Tiejun Qin; Yujiao Jia; Lijuan Pan; Qingyan Gao; Meng Jiao; Bing Li; Robert Peter Gale; Zhijian Xiao

doi:10.1080/10428194.2023.2226277

Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement

Leuk Lymphoma. 2023 Sep;64(9):1605-1610. doi: 10.1080/10428194.2023.2226277. Epub 2023 Jun 24.

Authors

Yiru Yan^{1

2}, Shiqiang Qu^{1

2

3}, Jinqin Liu^{1

2}, Chengwen Li⁴, Xiao Yan⁵, Zefeng Xu^{1

2

3}, Tiejun Qin³, Yujiao Jia⁴, Lijuan Pan³, Qingyan Gao³, Meng Jiao³, Bing Li^{1

2

3}, Robert Peter Gale⁶, Zhijian Xiao^{1

2

3

4}

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China.
² Tianjin Institutes of Health Science, Tianjin, P.R. China.
³ MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China.
⁴ Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China.
⁵ Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo Clinical Research Center for Hematologic Malignancies, Ningbo, P.R. China.
⁶ Centre for Hematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, United Kingdom.

PMID: 37354441
DOI: 10.1080/10428194.2023.2226277

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Benzamides
Eosinophilia* / genetics
Gene Rearrangement
Humans
Lymphoma* / complications
Myeloproliferative Disorders* / diagnosis
Myeloproliferative Disorders* / drug therapy
Myeloproliferative Disorders* / genetics
Receptor, Fibroblast Growth Factor, Type 1 / genetics
Translocation, Genetic

Substances

olverembatinib
Benzamides
Receptor, Fibroblast Growth Factor, Type 1
FGFR1 protein, human

Grants and funding

DH_/Department of Health/United Kingdom